Response and effectiveness
Top 6 in Top 7 Things to Know About Entresto
In clinical trials, Entresto outperformed enalapril in lowering the risk of cardiovascular death or hospitalization for heart failure. Entresto also increased overall survival rates. These findings were consistent across all subgroups studied.
Entresto reduced baseline NT-proBNP in children aged one to less than 18 years by 44% compared to 33% with enalapril, indicating improved cardiovascular outcomes in pediatric patients.
